Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

Celgene’s apremilast set for 2013 filing

Pharma company releases positive phase III results for psoriasis candidate

- PMLiVE

Injectables land-grab set to continue as Hikma reports offers

Comes just days after Mylan strikes a major deal to increase its presence in the area

- PMLiVE

Boehringer partners with PatientsLikeMe on rare disease community

Collaborates with the online patient community on idiopathic pulmonary fibrosis

- PMLiVE

Keying in loyalty

Why you need to put return on engagement (RoE) above all else

- PMLiVE

ALK Abello appoints UK managing director

Sean Connor joins from Shire

- PMLiVE

Blind date: client-agency relationships

Thanks to today’s business pressures, ‘chemistry’ – once seen as the bedrock of client-agency relationships – has been sidelined in favour of increasingly complex RFIs that form a wedge between...

- PMLiVE

Communicating clearly: using PowerPoint properly

How to design and use data slides that really add to your presentation.

INC Research appoints new EVP, APAC

Garth Tierney co-founded Australian CRO Trident Clinical Research

- PMLiVE

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of €5.5bn by 2015

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

Social media crisis management in healthcare

In a guest blog Uri Goren outlines a crisis toolkit for pharma

Novartis building

Novartis’ Ilaris cleared for gouty arthritis in EU

First biologic drug approved for condition in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links